A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to developing more efficient cancer detection methods and …

This overview of the fifth edition of the WHO classification of thymic epithelial tumors
(including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]) …

Background Treatment options are limited for patients with thymic carcinoma. These
aggressive tumours are not typically associated with paraneoplastic autoimmune disorders …

Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction
disorders. Although a plethora of immunosuppressive treatments exist, no cure is available …

Myasthenia gravis (MG) is a neurological disease caused by autoantibodies against
neuromuscular-associated proteins. While MG frequently develops in thymoma patients, the …

Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial
origin characterized by varying degrees of lymphocytic infiltration and a predisposition …

The thymus prevents autoimmune diseases through mechanisms that operate in the cortex
and medulla, comprising positive and negative selection and the generation of regulatory T …

Background Patients with advanced type B3 thymoma and thymic carcinoma resistant to
chemotherapy have few treatment options. We report the efficacy and safety results of the …

The WHO classification system of tumors is adopted worldwide and is fundamental to how
tumor or tumor-like conditions are clinically managed or treated. It is considered the …

Thymic carcinomas are rare malignancies that in general arise in the prevascular (anterior)
mediastinum. These tumors are usually invasive, often present at advanced stages, and …